Altamira Therapeutics Announces European Patent Office Decision To Grant For Patent Application Covering Intranasal Betahistine
Portfolio Pulse from Benzinga Newsdesk
Altamira Therapeutics Ltd. (NASDAQ:CYTO) has received an 'Intention to Grant' notice from the European Patent Office for its patent application titled 'Intranasal Composition Comprising Betahistine'. The patent, expected to remain valid until February 2038, will provide key intellectual property protection for the company's intranasal betahistine program (AM-125) in Europe. The patent has been granted in around 50 countries worldwide, including key markets in North America and Europe.
November 10, 2023 | 1:47 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Altamira Therapeutics has received a key patent grant for its intranasal betahistine program, which could strengthen its position in the market and potentially increase its revenues.
The granting of a patent for Altamira's intranasal betahistine program strengthens the company's intellectual property portfolio and provides protection against competitors. This could potentially lead to increased revenues as the company can exclusively market this product in the regions where the patent is valid. Therefore, this news is likely to have a positive impact on the company's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100